يعرض 2,581 - 2,600 نتائج من 18,221 نتيجة بحث عن 'significantly ((((((we decrease) OR (a decrease))) OR (greatest decrease))) OR (linear decrease))', وقت الاستعلام: 0.41s تنقيح النتائج
  1. 2581

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  2. 2582

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  3. 2583

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  4. 2584

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  5. 2585

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  6. 2586

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  7. 2587

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  8. 2588

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  9. 2589
  10. 2590
  11. 2591
  12. 2592
  13. 2593
  14. 2594
  15. 2595
  16. 2596
  17. 2597
  18. 2598

    Image1_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.tif حسب Wenzhe Li (815057)

    منشور في 2024
    "…</p>Methods<p>Using the CTD, GeneCards, and GSEA databases, we identified WFS1 as a diabetes-related gene and then conducted an extensive investigation focusing on WFS1 in the context of EC. …"
  19. 2599

    Table2_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.xlsx حسب Wenzhe Li (815057)

    منشور في 2024
    "…</p>Methods<p>Using the CTD, GeneCards, and GSEA databases, we identified WFS1 as a diabetes-related gene and then conducted an extensive investigation focusing on WFS1 in the context of EC. …"
  20. 2600

    Table3_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.docx حسب Wenzhe Li (815057)

    منشور في 2024
    "…</p>Methods<p>Using the CTD, GeneCards, and GSEA databases, we identified WFS1 as a diabetes-related gene and then conducted an extensive investigation focusing on WFS1 in the context of EC. …"